---
title: "Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Phase of product development"
description: "Formulary evidence on Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Phase of product development. Topics: Regulatory status: Submission planned; BLA planned for 2027; Development phase: phase 3, with phase 3 treatment continuing to 52 weeks; Additional phase 3 results anticipated in February 2027; Phase 3 topline results reported in September 2026; 9 further topics. 13 evidence topics quoted from 16 sources."
canonical: "https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/product-information-and-disease-description/phase-of-product-development"
published: "2026-11-18T22:38:31-05:00"
modified: "2026-11-18T22:38:31-05:00"
---

# Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Phase of product development

<a id="heading-2.1.1"></a>

## 2.1.1 Phase of Product Development

<a id="topic-2.1.1-1"></a>

### Regulatory status: Submission planned; BLA planned for 2027

> “BLA submission for barzolvolimab in CSU anticipated in 2027”
> “Treatment in both EMBARQ-CSU trials will continue to 52 weeks, and the Company anticipates a BLA submission in 2027.”

Source: [Celldex third quarter results release (2026)](https://ir.celldex.com/news-releases/news-release-details/celldex-reports-third-quarter-financial-results-and-provides)

> “Treatment will continue in both trials to 52 weeks, and a Biologics License Application (BLA) submission to the FDA is anticipated in 2027.”
> “We plan to present EMBARQ-CSU data at an upcoming medical meeting and submit a BLA to the FDA in 2027.”

Source: [Celldex Form 10-Q, third quarter (2026)](https://www.sec.gov/Archives/edgar/data/744218/000110465926123322/cldx-20260930x10q.htm)

> “The Company intends to present the EMBARQ-CSU data at an upcoming medical meeting and plans to submit a Biologics License Application (BLA) to the FDA in 2027.”

Source: [Celldex EMBARQ-CSU topline release (2026)](https://ir.celldex.com/news-releases/news-release-details/celldex-announces-positive-results-phase-3-embarq-csu1-and)

> “Results support planned BLA submission in 2027”

Source: [Celldex presentation, EMBARQ-CSU topline results call (2026)](https://ir.celldex.com/static-files/2a5b3af9-c496-4dd6-a011-6490b86c7bc2)

<a id="topic-2.1.1-2"></a>

### Launch

No evidence found.

<a id="topic-2.1.1-3"></a>

### Development phase: phase 3, with phase 3 treatment continuing to 52 weeks

> “Barzolvolimab is in Phase 3 development.”

Source: [Celldex Form 10-Q, third quarter (2026)](https://www.sec.gov/Archives/edgar/data/744218/000110465926123322/cldx-20260930x10q.htm)

> “The EMBARQ-CSU trials are ongoing, with treatment continuing through 52 weeks.”
> “The Phase 3 EMBARQ-CSU1 and CSU2 studies are ongoing. A BLA submission is planned for 2027.”

Source: [Celldex EMBARQ-CSU topline release (2026)](https://ir.celldex.com/news-releases/news-release-details/celldex-announces-positive-results-phase-3-embarq-csu1-and)

<a id="topic-2.1.1-4"></a>

### Additional phase 3 results anticipated in February 2027

> “Additional 24-week Phase 3 results anticipated in February 2027”

Source: [Celldex presentation, EMBARQ-CSU topline results call (2026)](https://ir.celldex.com/static-files/2a5b3af9-c496-4dd6-a011-6490b86c7bc2)

<a id="topic-2.1.1-5"></a>

### Phase 3 topline results reported in September 2026

> “HAMPTON, N.J., Sept. 22, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) today reported positive topline results from the Company’s Phase 3 EMBARQ-CSU1 and EMBARQ-CSU2 trials evaluating two doses of barzolvolimab in patients with chronic spontaneous urticaria (CSU) whose symptoms are inadequately controlled by H1-antihistamines.”
> “Data cutoff: September 9, 2026”

Source: [Celldex EMBARQ-CSU topline release (2026)](https://ir.celldex.com/news-releases/news-release-details/celldex-announces-positive-results-phase-3-embarq-csu1-and)

<a id="topic-2.1.1-6"></a>

### Phase 3 enrollment completed in February 2026

> “HAMPTON, N.J., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today the completion of enrollment in the Company’s global Phase 3 program of barzolvolimab in chronic spontaneous urticaria (CSU), which consists of two Phase 3 trials—EMBARQ-CSU1 and EMBARQ-CSU2.”
> “Enrollment completed six months ahead of guidance, driven by significant unmet need for better treatments in CSU”

Source: [Celldex EMBARQ-CSU enrollment release (2026)](https://ir.celldex.com/news-releases/news-release-details/celldex-completes-enrollment-global-phase-3-studies-embarq-csu1)

<a id="topic-2.1.1-7"></a>

### Phase 3 trials initiated in July 2024

> “In July 2024, we initiated two Phase 3 studies of barzolvolimab in CSU.”

Source: [Celldex Form 10-Q, third quarter (2026)](https://www.sec.gov/Archives/edgar/data/744218/000110465926123322/cldx-20260930x10q.htm)

> “HAMPTON, N.J., July 16, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today the initiation of its global Phase 3 program, consisting of two Phase 3 trials (EMBARQ-CSU1 and EMBARQ-CSU2) designed to establish the efficacy and safety of barzolvolimab in adult patients with CSU who remain symptomatic despite H1 antihistamine treatment.”

Source: [Celldex EMBARQ-CSU initiation release (2024)](https://ir.celldex.com/news-releases/news-release-details/celldex-therapeutics-initiates-global-phase-3-program)

<a id="topic-2.1.1-8"></a>

### Phase 2 study: first participant dosed in June 2022

> “HAMPTON, N.J., June 21, 2022 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that the first patient has been dosed in a Phase 2 clinical study of barzolvolimab for the treatment of chronic spontaneous urticaria (CSU).”

Source: [Celldex phase 2 CSU first patient dosed release (2022)](https://ir.celldex.com/news-releases/news-release-details/celldex-announces-first-patient-dosed-phase-2-study)

<a id="topic-2.1.1-9"></a>

### Subcutaneous formulation phase 1 study in healthy volunteers: first cohort dosed in September 2021

> “HAMPTON, N.J., Sept. 13, 2021 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that the first cohort has been dosed in the Phase 1 study of the subcutaneous formulation of CDX-0159 in healthy volunteers.”

Source: [Celldex subcutaneous formulation study release (2021)](https://ir.celldex.com/news-releases/news-release-details/celldex-announces-initiation-cdx-0159-subcutaneous-formulation)

<a id="topic-2.1.1-10"></a>

### Phase 1b study in chronic spontaneous urticaria: first participant dosed in October 2020

> “HAMPTON, N.J., Oct. 13, 2020 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) announced today that enrollment has opened and the first patient has been dosed in its randomized, double-blind Phase 1b study of CDX-0159 in patients with chronic spontaneous urticaria (CSU).”
> “As previously presented, CDX-0159 demonstrated a favorable safety profile as well as profound and durable reductions of plasma tryptase, indicative of systemic mast cell ablation in a Phase 1a single dose, healthy volunteer study.”

Source: [Celldex phase 1b CSU initiation release (2020)](https://ir.celldex.com/news-releases/news-release-details/celldex-therapeutics-initiates-phase-1b-study-cdx-0159-chronic)

<a id="topic-2.1.1-11"></a>

### Development in other indications: cold urticaria, symptomatic dermographism, atopic dermatitis, prurigo nodularis, and eosinophilic esophagitis

> “Enrollment is ongoing in Celldex’s global Phase 3 study in cold urticaria (ColdU) and symptomatic dermographism (SD)—EMBARQ-ColdU and -SD.”
> “Enrollment is complete in the Phase 2 study in atopic dermatitis (AD).”
> “Topline data from this study are expected to be presented in late 2026.”
> “Topline data from the Phase 2 study in prurigo nodularis (PN) were presented in July 2026 and suggested that mast cells may not be the key pathogenic driver in PN. Based on these results, Celldex is discontinuing the Phase 2 PN study.”
> “Additional indications for barzolvolimab will be announced by year end.”

Source: [Celldex third quarter results release (2026)](https://ir.celldex.com/news-releases/news-release-details/celldex-reports-third-quarter-financial-results-and-provides)

> “today reported topline results from the Company’s ongoing Phase 2 study of barzolvolimab in eosinophilic esophagitis (EoE), a chronic inflammatory disease of the esophagus.”
> “Based on these results, Celldex will not advance development in EoE.”

Source: [Celldex eosinophilic esophagitis phase 2 results release (2025)](https://ir.celldex.com/news-releases/news-release-details/celldex-reports-results-phase-2-study-barzolvolimab-eosinophilic)

<a id="topic-2.1.1-12"></a>

### FDA expedited program designations for chronic spontaneous urticaria

No evidence found.

<a id="topic-2.1.1-13"></a>

### Patent protection: U.S. composition of matter patent with estimated expiry in 2034

> “A composition of matter patent has been issued in the U.S. which would have an estimated patent expiry date in 2034 (this includes additional term due to PTA, but does not include any PTE if this may be secured in due course) and further U.S. patent applications are pending.”
> “Where issued the foregoing would have estimated normal patent expiry dates ranging from 2032 to 2033.”
> “Further (later filed) patent applications (relating to Fc sequences used in barzolvolimab and certain uses of barzolvolimab) are pending in the U.S., the European Patent Office, Japan, Canada, China, Australia, New Zealand, Israel, India, the Republic of Korea, the Eurasian Patent Office, Singapore, Brazil, Mexico and South Africa. If, when and where issued the latter would have estimated normal patent expiry dates in 2042.”

Source: [Celldex Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/744218/000110465926019652/cldx-20251231x10k.htm)

<a id="topic-2.1.1-14"></a>

### Phase 3 topline timing, July 2026 to August 2026, superseded in September 2026

> “Phase 3 CSU topline data expected in Sept/Oct 2026; Phase 3 SD and ColdU Enrollment On Track; Phase 2 topline data in AD in late 2026”

Source: [Celldex prurigo nodularis phase 2 results release (2026)](https://ir.celldex.com/news-releases/news-release-details/celldex-reports-results-phase-2-study-barzolvolimab-prurigo)

> “Barzolvolimab Phase 3 chronic spontaneous urticaria studies (EMBARQ-CSU 1 and 2) ongoing, topline data expected in Sept/Oct 2026; BLA submission planned for 2027”

Source: [Celldex second quarter results release (2026)](https://ir.celldex.com/news-releases/news-release-details/celldex-reports-second-quarter-financial-results-and-provides)

<a id="topic-2.1.1-15"></a>

### Phase 3 topline timing, February 2026 to June 2026, superseded in July 2026

> “Enrollment completed in both Phase 3 chronic spontaneous urticaria global registration studies (EMBARQ-CSU 1 and 2) six months ahead of guidance; Topline data expected in Q4 26; BLA submission planned for 2027”

Source: [Celldex fourth quarter 2025 results release (2026)](https://ir.celldex.com/news-releases/news-release-details/celldex-reports-fourth-quarter-and-year-end-2025-financial)

> “Topline data expected Q4 2026”
> “BLA submission planned for 2027”

Source: [Celldex EMBARQ-CSU enrollment release (2026)](https://ir.celldex.com/news-releases/news-release-details/celldex-completes-enrollment-global-phase-3-studies-embarq-csu1)

> “Enrollment completed six months ahead of guidance in both barzolvolimab Phase 3 chronic spontaneous urticaria studies (EMBARQ-CSU 1 and 2); Topline data expected in Q4 26; BLA submission planned for 2027”

Source: [Celldex first quarter results release (2026)](https://ir.celldex.com/news-releases/news-release-details/celldex-reports-first-quarter-financial-results-and-provides)

> “Results continue to support ongoing Phase 3 trials of barzolvolimab in CSU; topline data expected in Q4 2026”
> “Topline data are anticipated in Q4 2026, supporting a planned BLA submission in 2027.”

Source: [Celldex EAACI 2026 angioedema release (2026)](https://ir.celldex.com/news-releases/news-release-details/celldex-presents-long-term-barzolvolimab-results-demonstrating)

## Related pages
- [Barzolvolimab (CDX-0159): Chronic spontaneous urticaria](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria.md)
- [Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Terms and abbreviations](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/terms-and-abbreviations.md)
- [Barzolvolimab (CDX-0159): Chronic spontaneous urticaria](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/executive-summary) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/executive-summary.md)
- [Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Product information and disease description](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/product-information-and-disease-description.md)
- [Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Clinical evidence](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/clinical-evidence.md)
- [Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: Economic information and modeling report](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/economics) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/economics.md)
- [Barzolvolimab (CDX-0159) in Chronic spontaneous urticaria: References](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/references) · [Markdown](https://www.evicenter.com/drugs/barzolvolimab--chronic-spontaneous-urticaria/references.md)
